Scemblix (Asciminib) for Leukemia

Overview
Scemblix is approved by the U.S. Food and Drug Administration (FDA) to treat adults with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia, or Ph+ CML, in its early stages. Scemblix may be used for people who are newly diagnosed, have already tried other treatments, or have a specific gene mutation called T315I. Scemblix is also known by its drug name, Asciminib.

Scemblix is a type of medicine called a kinase inhibitor. It works by blocking a protein that helps cancer cells grow in people with Ph+ CML. By blocking this protein, Scemblix can help slow down the spread of leukemia.

How do I take it?
Prescribing information states that Scemblix is taken as a tablet by mouth. For Ph+ CML in the early phase, the recommended dose is either one dose daily or two smaller doses twice a day. For people with the T315I mutation, the recommended dose is two larger doses daily. Scemblix should be taken on an empty stomach. A person should not eat for two hours before and one hour after taking it. The tablets should be swallowed whole, without chewing or crushing them. Scemblix should be taken exactly as prescribed.

Side effects
Common side effects of Scemblix include pain in muscles and bones, rash, feeling tired, infections in the upper respiratory tract (like colds), headache, stomach pain, and diarrhea. Some people may also have changes in blood tests, like lower numbers of certain blood cells or changes in cholesterol and liver levels.

Rare but serious side effects may include very low blood cell counts, problems with the pancreas (a gland that helps with digestion), high blood pressure, allergic reactions, heart problems, and risks for unborn babies if taken during pregnancy. Your doctor may monitor these side effects and adjust treatment if needed.

For more information about this treatment, visit:

Label: Scemblix — Asciminib Tablet, Film Coated — DailyMed